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Abstract
Introduction: The use of opioids is fundamental in moderate and severe pain management. There is an 
increase in opioids use in highly developed countries, while at the same time in other countries, difficulties 
in access to appropriate pain treatment are observed. The aim of the study was to determine the use of 
opioids in the treatment of chronic cancer-related and non-cancer pain. 
Material and methods: The study covered the medical documentation of patients under the care of the 
Pain Medicine Clinic, Palliative Medicine Clinic and Hospice in the period 01.01.2017–30.04.2017 which 
reported: sex, age, duration of medical services, primary diagnosis, opioid treatment — pharmacological 
substances, a form of supply and side effects.
Results. In the study, 634 medical consultations of 196 patients were analyzed and 32 (16%) of them were 
cancer patients. The predominant cause of pain were degenerative diseases, disorders of the spinal nerves 
and nerve plexuses. Oxycodone was most often used as a monotherapy for cancer and non-cancer pain. 
Transdermal buprenorphine was significantly more frequently used in non-cancer pain and transdermal 
fentanyl was more frequently administered in cancer-related pain. In the group of cancer patients, the 
principles of multi–modal therapy were more often applied and no adverse effects were noted.
Conclusions. Opioids are the primary method in pharmacotherapy at the specialist level. Oxycodone is 
widely used in monotherapy of cancer-related and non-cancer pain. Various forms of the supply of opioids 
in the therapy of chronic cancer pain is not associated with the risk of side effects.
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Introduction
Pain is an unpleasant subjective experience with 
a multi-directional aspect: psychological, social and 
health, and at the same time constitutes a significant, 
current and interdisciplinary medical issue [1, 2]. Phar-
macological management is one of the methods of 
pain treatment. Opioid analgesics play a fundamental 
role in the pharmacotherapy of moderate to severe 
pain, both cancer and non-cancer pain. In moderate 
pain intensity defined in the Numerical Rating Scale 
(NRS) 4–6, step 2 opioids: tramadol, dihydrocodeine, 
codeine or small doses of step 3 opioids are rec-
ommended. Pain, corresponding to NRS 7–10, is 
an indication for the use of step 3 opioids at higher 
doses morphine, oxycodone, alternatively fentanyl or 
buprenorphine in the transdermal patch. Numerous 
publications indicate the increasing use of opioids in 
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recent decades in highly developed countries, while 
at the same time pointing to the difficulties in access 
to appropriate treatment and pain relief [3, 4].
In Poland, specialist and multidisciplinary treat-
ment including pharmacology, interventional tech-
niques, rehabilitation, and psychological interventions 
of patients with chronic pain take place in Pain Med-
icine Clinics, Palliative Medicine Clinics, Home and 
Stationary Hospices and In–patient Palliative Medicine 
Units in hospitals. The use of opioids in the treatment 
of chronic cancer and non–cancer pain still raises 
social controversies due to fears of the occurrence 
of mental and physical dependence. Given the dy-
namically growing number of people suffering from 
chronic pain and the increasing use of opioids in 
the treatment, medical personnel must demonstrate 
specialized knowledge and attention to this group 
of patients [5].
The use of opioids in pain treatment may be 
associated with a number of side effects and disor-
ders. Many of them are widely known and evaluated 
in a routine visit. Some of them are described as cog-
nitive decline and memory loss. The question arises 
whether the use of opioids for analgesia influences 
cognitive processes assessed in a typical medical 
examination on a standard control visit: Is this effect 
commonly reported by patients? The aim of this study 
is to determine the differentiation of using opioids 
in the treatment of cancer–related and non–cancer 
chronic pain. The second problem is what side ef-
fects of opioids are shown in the medical records on 
routine patient visits. This work is part of the project: 
Evaluation of pharmacological chronic pain treatment.
Material and methods
The study consisted of the analysis of medical doc-
umentation of patients under the care of the Pain Med-
icine Clinic, Palliative Medicine Clinic, Home Hospice 
in Białystok, Poland in the period from 01.01.2017 to 
30.04.2017. The data including information on sex, 
age, duration of treatment, principal diagnosis, opi-
oids prescriptions, applied pharmacological treatment 
with opioids — pharmacological substances, form 
of supply, side effects (constipation, skin changes, 
nausea, vomiting, cognitive disorders, memory loss, 
the need for psychological or psychiatric consultation) 
were noticed.
In all patients, in the field of nursing activities be-
fore a medical examination, the physical condition was 
assessed by measuring blood pressure by the non-in-
vasive method, heart rate, and pulsoximetry. NRS and 
visual–analogue scale (VAS) were used to analyze 
the intensity of pain. Another nursing element was 
a closed question questionnaire aimed at identifying 
behaviours related to the abuse of opioid drugs and 
accepting treatment. As the study was observational 
in its nature an Ethical Committee approval was not 
required. The total group of patients, the total num-
ber of medical consultations and the total number of 
opioids prescriptions were noticed.
Conformity assessment of the empirical distri-
bution of studied parameters was performed using 
the Shapiro–Wilk test. Since most empirical obtained 
distributions differed significantly from normal dis-
tributions, a comparison of the data was assessed 
by non-parametric tests. The differences in the level 
of parameters being considered between the groups 
of patients were analyzed using the Mann-Whitney 
U test. Coefficient correlation was calculated us-
ing Spearman’s rank method. Probability values of 
p < 0.05 were accepted as significant. Group data 
were expressed as medians and ranged when appro-
priate. Obtained results were subjected to statistical 
analysis using the STATISTICA 12.0 (StatSoft Inc., Tulsa, 
OK, United States) software.
Results
The characteristics of the patients studied are 
presented in Table 1. In the group of patients with 
chronic non–cancer pain, the most frequent cause 
for providing medical care were classified by Interna-
tional Classification Diseases (ICD-10) as chronic pain 
(R 52.1), pain in the course of spine degenerative 
disease (M 51, M 15, M 50, M 47), hip joints (M 16) 
and disorders of spinal nerves and nerve plexuses 
Table 1. Characteristic of study group. Diagnosis in 
chronic non–cancer pain according to ICD-10 classifi-
cation: R52.1, G54, M15, M16, M17, M47, M50, M51
Total number of patients/
/number of medical consultations 196/634 
Age in years, mean (range) 66.3 (33–101)
Female 114
Male 82
Pain Medicine Clinic 164
Palliative Medicine Clinic 24
Home Hospice 8
Cancer diagnosis 32
Non-cancer diagnosis 164
R 52.1 52
G 54 36
M 15, M 16, M 17, M 47, M 50, M 51 76
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(G 54). The group of 32 (16.3%) patients were treated 
for cancer pain.
The analysis presented that in non-cancer pain, 
only please provide a number of patients 5% of the 
patients were treated with opioid therapy before 
a visit to the Pain Medicine Clinic, most often with 
transdermal buprenorphine. Among the patients who 
were initially provided with services at the Pain Med-
icine Clinic, opioids were prescribed in a number of 
patients please 20% of cases.
The analysis showed that in the total study group 
(196 patients) 634 medical consultations were per-
formed and opioids were prescribed 884 times. The 
oral route of opioids administration in non-cancer 
pain treatment was used 605 times and transdermal 
patches were administered 174 times. In the treatment 
of non-cancer pain with the use of opioids, therapy 
with oral oxycodone (288 times) was significantly 
more frequent (p < 0.05) than with transdermal 
buprenorphine (132 times). The analysis showed that 
oral tramadol, oral oxycodone and buprenorphine 
in the sublingual form were used significantly more 
frequently than morphine products, while oxycodone 
was recommended considerably more often for all oral 
analgesics. It was noticed that transdermal buprenor-
phine was used much more frequently than transder-
mal fentanyl (p < 0.05). The characteristic of types 
of opioids and correlations are presented in Figure 1.
In the analyzed period, 16 adverse reactions re-
lated to non-cancer pain treatment were reported, 
including nausea and vomiting accounted please 
provide number of patients with all percentage values 
40%, skin lesions and itching 40%, constipation for 
15%, persistent, mental changes 5% — in these cases 
patients referred for specialist treatment — psycho-
logical and psychiatric. The analysis showed that there 
is no statistical correlation between the occurrence 
of adverse reactions associated with the use of oral 
opioids and age and sex of patients. However, there 
was a correlation between the presence of adverse 
reactions and transdermal opioids. The results of the 
study demonstrated a correlation of side effects and 
the use of buprenorphine (p = 0.05), no correlation 
observed with fentanyl products. In non-cancer pain 
therapy, the side effects were reported in 13 cases 
of transdermal opioids, which is 7.47% of the total 
group. Side effects have also been reported for three 
opioid applications in the oral form, accounting for 
only 0.49% of all applications.
In the study, 105 opioids prescriptions were provid-
ed for a total of 32 cancer patients (15 women with 
an average age of 72.6 and 17 men with an average 
age of 68.2 years, the average duration of medical care 
was 29.4 months, average 1.25 visits/month/patient). 
In a number of patients please 33% of cases, mono-
therapy used in the treatment, with the most common 
use of oxycodone products. The multi-modal pain ther-
apy was noticed in a number of patients please 67% of 
cases, it is shown that the most common combinations 
were fentanyl or buprenorphine in the transdermal 
system and oral morphine. No side effects have been 
reported in those subjects. A summary of the results:
1. Oral forms of opioids were the most common used 
in non-cancer pain therapy.
2. Oxycodone was used more frequently in cancer 
and non-cancer pain therapy.
Figure 1. The use of opioids in the treatment of cancer and non-cancer pain. Numbers present total specific opioids 
drug prescriptions
Fentanyl fast-action form
Fentanyl transdermal system
Buprenorphine transdermal system
Tapentadol
Methadon
Morphine
Oxycodone
Buprenorphine sublingual
Tramadol/Paracetamol
TramadolA
4
42
21
132
9
2
3
55
22
26
131
288
9
2
10
0
*
*
*
**
128
50 100 150 200 250 300 350
*p < 0.05 with respect to morphine
**p < 0.05 with respect to transdermal fentanyl
Non-cancer pain Cancer pain
Palliative Medicine in Practice 2019, tom 13, nr 1
www.journals.viamedica.pl/palliative_medicine_in_practice14
3. Buprenorphine transdermal systems in non-cancer 
pain and fentanyl transdermal form in cancer-re-
lated pain were more frequently used.
4. The correlation of adverse reactions and the use of 
opioids in the treatment of non–cancer pain was 
noticed. There was no correlation in the group of 
cancer patients.
5. Combination of oral and transdermal forms of 
opioids in cancer pain therapy was most popular.
Discussion
During the 4-month follow-up carried out in Pain 
Clinic, the Palliative Medicine Clinic and Home Hospice 
care, it was shown that oxycodone and buprenorphine 
were significantly more frequently recommended 
than other opioids in the treatment of non-cancer 
pain. These drugs were most often used in the treat-
ment of strong refractory pain in the course of degen-
erative disease of the spine, joints, and other muscu-
loskeletal chronic pain. Also were observed that the 
treatment of non-cancer pain, a monotherapy regimen 
was much more common compare to cancer-related 
pain. It has been observed that patients referred to 
pain clinics have pain opioid therapy which is ordered 
before arrival at the clinic and started by primary care. 
The most often used opioid before visiting a specialist 
pain clinic was buprenorphine. The results of our study 
are comparable with the analyzes of opioid prescribing 
for chronic musculoskeletal pain in UK primary care 
[6]. Also earlier our analysis of the use of opioids in the 
clinic demonstrated that transdermal buprenorphine 
constituted about 50% of the prescription of opioids 
in non-cancer pain [5]. In our study, it was demon-
strated that, unlike the treatment of non-cancer pain, 
the pain associated with cancer required multi–modal 
therapy. In the treatment of cancer-related pain, the 
most common form of short-acting morphine is used 
in combination with the fentanyl or buprenorphine 
transdermal system. The results of our study indicate 
that the use of synthetic opioids — in this case, oxy-
codone and various forms of buprenorphine — was 
significantly more frequent compared to the natural 
opiate, which is morphine. These results show that 
therapy based on synthetic opioids is more preferred 
in non-cancer pain.
The specific objective of the study was to analyze 
the use of opioids, and especially the answer to the 
question of whether the doctor prefers the choice 
of opioids? No differences were found in the use of 
opioids between individual doctors, especially there 
was no difference depending on the place where the 
medicine was being prescribed. The type of opioid 
selection depends on the cause of pain and when 
the pain was of non-cancer origin, mainly oxycodone 
and buprenorphine were used. Conversely, in patients 
with cancer-related pain, the therapy was complex 
and a wider choice of drugs was used.
Both in the world and in Poland, there is an in-
crease in opiate consumption, especially in non-cancer 
pain [7]. According to previous data from the litera-
ture, the use of synthetic opioids is associated with 
lower risk of cognitive, gastrointestinal disorders, drug 
interactions compared to treatment associated with 
the use of morphine. However, in recent years, the 
phenomenon of excessive use of opioids, especially 
oxycodone, has been observed in the USA in partic-
ular, not related to the occurrence of pain. This is 
related to the occurrence of a number of side effects 
including overdose.
It should be noted that irrespective of the dose 
of the drug, CNS side effects may occur. It is really 
thought-provoking that the small group of patients 
had cognitive disorders occurring after using the 
opioids. According to the literature, such symptoms 
may occur and they are most frequently reported in 
the USA [8–15]. Mumba et al. presented that mental 
and cognitive dysfunction associated with opioid 
therapy appears in about 10% of patients [16]. In 
experimental studies, it has been described that the 
opioid dose is associated with the functional stimu-
lation of the hippocampus and amygdala structures 
with concurrent inhibition of brain cerebral cortex, 
and large opioid doses also inhibit the neuronal 
activity of the thalamus. As a result of the described 
changes, there is a disturbance of motor, sensory and 
cognitive functions and emotional disturbances. The 
assessment of cognitive impairment is difficult and 
requires the use of specialist assessment, including 
tests and psychological assessment [1, 2].
During the period 2000–2015 in Poland there 
was a significant increase in the use of opioids. The 
progressive increase in the use of opioids in analgesic 
therapy had been reported since 2013, including step 
3 opioids, accounted for 41% of consumption. Many 
years of observation indicated increased use of both 
step 2 and step 3 opioids, which reached a value from 
14.1 mg oral morphine/patient in 2000 to 44.4 mg 
in 2015. Regarding step 2 opioids, the increase was 
less dynamic and reached values from 21.9 mg oral 
morphine equivalent dose (2000) up to 59 mg (2015). 
When analyzing the group of step 3 opioids during 
the study period, the authors showed the reduced 
use of morphine. In the initial stage of observation, 
morphine was an opioid widely used and accounted 
for about 75% of all opioids used in pain therapy. In 
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2015, in comparison to 2000, it was used in size range 
from 8.9 to 10 mg/patient and currently, this com-
pound remains in the third place in the classification 
of the use of opioids. In the analyzed period, there 
was a systematic increase in the use of opioid med-
ications in the form of transdermal patches — fen-
tanyl and buprenorphine. The authors pointed out 
that oxycodone, which has been available in Poland 
since 2009, remains in increased use and currently, 
it occupies the 4th place in the group of step 3 opi-
oids. Methadone and pethidine have less importance 
in the treatment of pain. In the group of step 2 opi-
oids, tramadol, which at the same time constituted 
50% of all opioids, was used most frequently in the 
studied period. The use of dihydrocodeine is constant 
and reaches 0.7–0.8 mg of oral morphine/patient. In 
2000 step 3 opioids constituted 34% of all prescribed 
opioids, however, in the period 2013–2015 there was 
an increase to 41% [17].
Many interdisciplinary publications emphasize that 
the use of opioids in the treatment of chronic pain 
has a strong medical recommendation [18–22]. In our 
study, a small aspect of chronic pain therapy limited 
only to the use of opioid drugs was analyzed. The 
study included a 4-month period of medical services in 
the Pain Medicine Clinic, Palliative Medicine Clinic and 
Home Hospice where anesthesiologists and palliative 
medicine specialists work. The results of our study are 
consistent with the observations presented in numer-
ous publications, which indicate that oxycodone and 
buprenorphine are most often used in the treatment 
of non-cancer pain, while multi-modal therapy using 
morphine and another step 3 opioids is the funda-
mental principle treatment of cancer-related pain. The 
obtained results should be confirmed by multi-centre 
study in a more extended period.
Conclusions
1. Opioids are the primary method in pharmacothe-
rapy at the specialist level in palliative medicine.
2. Oxycodone is the most popular and widely used 
in cancer and non-cancer pain.
3. The occurrence of side effects in the form of mental 
disorders during opioid therapy is low.
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